+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Zaltrap"

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030 - Product Thumbnail Image

Colorectal Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Chemotherapy, Immunotherapy), By Region (North America, Asia Pacific, Latin America, Europe), And Segment Forecasts, 2023 - 2030

  • Report
  • September 2023
  • 100 Pages
  • Global
From
Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022 - Product Thumbnail Image

Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

  • Report
  • June 2018
  • 99 Pages
  • Global
From
Colorectal Cancer Forecast and Market Analysis to 2036 - Product Thumbnail Image

Colorectal Cancer Forecast and Market Analysis to 2036

  • Report
  • September 2018
  • 630 Pages
  • Global
From
Disease Analysis: Colorectal Cancer - Product Thumbnail Image

Disease Analysis: Colorectal Cancer

  • Report
  • May 2021
  • 88 Pages
  • Global
  • 4 Results (Page 1 of 1)
Loading Indicator

Zaltrap is a brand of colon cancer drug developed by Sanofi and Regeneron Pharmaceuticals. It is a monoclonal antibody that works by blocking the activity of vascular endothelial growth factor (VEGF), a protein that helps cancer cells grow and spread. Zaltrap is used in combination with chemotherapy to treat metastatic colorectal cancer in adults. It is approved by the U.S. Food and Drug Administration (FDA) and is available in the United States and Europe. The Zaltrap market is highly competitive, with several other drugs available to treat colon cancer. These include Avastin, Erbitux, and Stivarga. Each of these drugs has its own advantages and disadvantages, and physicians must weigh the risks and benefits of each drug when deciding which one to prescribe. Companies in the Zaltrap market include Sanofi, Regeneron Pharmaceuticals, Roche, Merck, and Bayer. Show Less Read more